Sitravatinib potentiates immune checkpoint blockade in refractory cancer models
Author:
Publisher
American Society for Clinical Investigation
Subject
General Medicine
Link
https://insight.jci.org/articles/view/124184/files/pdf
Reference19 articles.
1. Immune Checkpoint Blockade in Cancer Therapy
2. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
3. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
4. Oncology Meets Immunology: The Cancer-Immunity Cycle
5. The role of TAM family receptors in immune cell function: implications for cancer therapy;Paolino;Cancers (Basel),2016
Cited by 88 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Novel insights into immune cells modulation of tumor resistance;Critical Reviews in Oncology/Hematology;2024-10
2. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer;Cancer Immunology, Immunotherapy;2024-09-05
3. Hallmarks of pancreatic cancer: spotlight on TAM receptors;eBioMedicine;2024-09
4. Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer;Investigational New Drugs;2024-08-21
5. STAT6-targeting antisense oligonucleotides against solitary fibrous tumor;Molecular Therapy - Nucleic Acids;2024-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3